Eicosanedioic acid is a long-chain dicarboxylic acid linker that provides hydrophobicity in ADC and lipid-based drug conjugates. It is often used to modulate membrane interaction, enhance drug retention, or incorporate fatty acid chains in linker designs for antibody-drug conjugates and delivery systems.
Structure of 2424-92-2
* For research and manufacturing use only. We do not sell to patients.
Size | Price | Stock | Quantity |
---|---|---|---|
-- | $-- | In stock |
Looking for different specifications? Click to request a custom quote!
Capabilities & Facilities
Eicosanedioic acid, a long-chain dicarboxylic acid with the molecular formula C20H38O4, plays a critical role in pharmaceutical chemistry. Its structure, consisting of a 20-carbon alkyl chain flanked by carboxylic acid groups at both ends, confers unique properties that are highly valued in the development of therapeutic agents. The substantial hydrophobic core of the eicosanedioic acid molecule provides significant advantages when employed as a linker in drug conjugation technologies. In the realm of antibody-drug conjugates (ADCs), this compound serves as a non-cleavable linker, facilitating the stable and targeted delivery of cytotoxic drugs to cancer cells, thereby minimizing off-target effects and enhancing therapeutic efficacy.
The application of eicosanedioic acid extends beyond ADCs. In the realm of small molecule drug discovery, it is harnessed as a key component in the design of PROteolysis TArgeting Chimeras (PROTACs). These are bifunctional molecules engineered to target specific proteins for degradation via the ubiquitin-proteasome pathway. Eicosanedioic acid serves as a crucial linker that connects the target-binding ligand with the E3 ubiquitin ligase ligand. The rigidity and optimal length of the eicosanedioic acid linker ensure the correct spatial orientation necessary for the effective recruitment of the targeted protein to the proteasome, thereby facilitating its degradation. This innovative approach has unlocked new therapeutic possibilities for previously “undruggable” targets, marking a significant advancement in cancer therapy and other areas.
The dual utility of eicosanedioic acid in both ADCs and PROTACs underlines its versatility and significance in the field of medicinal chemistry. As a stable linker, it contributes to the pharmacokinetic properties and bioavailability of the conjugated drugs. In ADCs, the use of a non-cleavable linker like eicosanedioic acid ensures that the cytotoxic payload remains attached to the antibody until it is internalized by the target cell, thereby maximizing its potency. In contrast, the use of eicosanedioic acid in PROTACs underscores the molecule’s adaptability and effectiveness in mediating protein-protein interactions necessary for targeted protein degradation.
Contact our experts today for pricing and comprehensive details on our ADC offerings.
From cytotoxin synthesis to linker design, discover our specialized services that complement your ADC projects.
Learn more about payload design, linker strategies, and integrated CDMO support through our curated ADC content.
Find exactly what your project needs from our expanded range of ADCs, offering flexible options to fit your timelines and goals.